GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patientâ€™s immune systemâ€™s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	13.53M 11.66M 10.93M 9.98M 18.8M 1.29B 18.86M 130M 50.61M 653M 50.81M 49.7M 2.16B	P/E 2026 *	-0.7x	P/E 2027 *	-0.94x
Enterprise Value	13.53M 11.66M 10.93M 9.98M 18.8M 1.29B 18.86M 130M 50.61M 653M 50.81M 49.7M 2.16B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	94.09%	Yield 2026 *	-	Yield 2027 *	-

08-14	GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-30	GT Biopharma Reports Integration Of AI-Based Tools Across Discovery And Engineering Of Tumor-Targeting NK Cell Engagers And Multi-Domain Proteins	CI
06-08	Gt Biopharma Advances Three Trike Drug Candidates into Human Trials and Doses First Patient in Phase 1 Trial of Gtb-5550	CI
06-01	GT Biopharma, Inc. Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	CI
05-29	GT Biopharma Advances Three Trike Drug Candidates into Human Trials	CI
05-15	GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-14	GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors	RE
05-14	Gt Biopharma Inc Announces First Patient Dosed in Phase 1 Trial of Gtb-5550, A B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors	CI
04-07	GT Biopharma, Inc. Enters into Investigator Initiated Clinical Trial Agreement with Regents of the University of Minnesota	CI
03-02	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-01	GT Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-03	GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug for GTB-5550 TriKE, B7-H3-Targeted Natural Killer Cell Engager for Solid Tumors Expressing B7-H3	CI
02-03	GT Biopharma gets FDA IND clearance for GTB-5550 TRiKE, B7-H3-targeted NK engager for B7-H3+ solid tumors	RE

23-01-05	EF Hutton Starts GT Biopharma at Hold With $2 Price Target	MT
22-09-13	HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating	MT
22-08-12	Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9	MT
22-01-24	B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT
21-06-24	GT Biopharma : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating	MT

08-14	GT Biopharma Reports Second Quarter 2026 Financial Results	AQ
06-30	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs	AQ
06-12	After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell	AQ
06-08	Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet	AQ
06-01	GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	AQ

24-04-30	Caterpillar deja París, el cacao está menos caliente
24-04-30	Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud

Oxis International Stock OTC Bulletin Board

Stocks

US6918295014

Biotechnology & Medical Research

Valuation : Oxis International

Latest news : Oxis International

Analysts' recommendations : Oxis International

Press Releases : Oxis International

News in other languages : Oxis International

Quotes and Performance

Managers and Directors : Oxis International

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Michael Breen CEO	Chief Executive Officer	64	2022-03-01
Alan Urban DFI	Director of Finance/CFO	57	2024-06-02

Director	Title	Age	Since
Michael Breen CHM	Chairman	64	2021-12-14
Charles Casamento BRD	Director/Board Member	79	2023-04-30
Hilary Kramer BRD	Director/Board Member	62	2025-05-06

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXIS INTERNATIONAL	-4.10%	+3.79%	-	-	13.53M
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+91.62%	69.54B
ARGENX SE	-1.34%	-0.75%	+48.21%	+92.23%	64.97B
WUXI BIOLOGICS (CAYMAN) INC.	-4.56%	-0.37%	+34.57%	+9.67%	26.51B
INSMED INCORPORATED	-2.35%	-5.75%	-12.90%	+436.87%	25.89B
BIONTECH SE	-8.37%	-12.43%	+2.08%	-18.39%	25.64B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+429.04%	20.22B
GENMAB A/S	-0.51%	+0.23%	+35.77%	-19.61%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-4.92%	-6.46%	+0.66%	+539.48%	15.69B
EXELIXIS, INC.	-1.47%	+0.68%	+45.51%	+142.00%	13.49B
Average	-3.00%	-1.93%	+54.37%	+189.21%	31.33B
Weighted average by Cap.	-2.54%	-1.50%	+51.33%	+149.39%

	2026 *	2027 *
Net sales	-	-
Net income	-17.35M -14.95M -14.02M -12.8M -24.1M -1.66B -24.18M -166M -64.88M -837M -65.14M -63.72M -2.78B	-18.11M -15.61M -14.63M -13.36M -25.17M -1.73B -25.25M -174M -67.74M -874M -68.01M -66.53M -2.9B
Net Debt	-	-